Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclasta for Prevention of Periprosthetic Bone Loss After THR
NCT02838121Phase 3Completed
- Start
- Dec 2009
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zoledronic acid in periprosthetic osteolysis (PPO). Started Dec 2009; status: completed.
02
Drugs
zoledronic acid
03
Conditions
periprosthetic osteolysis (PPO)
Beyond the preview
Go deeper on NCT02838121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02838121.